Advisors Preferred LLC acquired a new position in C.R. Bard, Inc. (NYSE:BCR) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,339 shares of the medical instruments supplier’s stock, valued at approximately $429,000.
Several other institutional investors have also recently modified their holdings of BCR. Achmea Investment Management B.V. acquired a new stake in shares of C.R. Bard in the first quarter worth $2,525,000. Public Employees Retirement System of Ohio lifted its stake in shares of C.R. Bard by 1.3% in the first quarter. Public Employees Retirement System of Ohio now owns 76,648 shares of the medical instruments supplier’s stock worth $19,050,000 after buying an additional 1,000 shares during the last quarter. HM Payson & Co. lifted its stake in shares of C.R. Bard by 9.4% in the first quarter. HM Payson & Co. now owns 1,106 shares of the medical instruments supplier’s stock worth $275,000 after buying an additional 95 shares during the last quarter. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of C.R. Bard in the first quarter worth $39,971,000. Finally, Columbia Partners L L C Investment Management acquired a new stake in shares of C.R. Bard in the first quarter worth $415,000. Institutional investors and hedge funds own 79.27% of the company’s stock.
Several equities analysts recently commented on BCR shares. BidaskClub upgraded shares of C.R. Bard from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 8th. BMO Capital Markets reiterated a “hold” rating and set a $317.00 target price on shares of C.R. Bard in a research note on Tuesday, July 11th. Zacks Investment Research cut shares of C.R. Bard from a “buy” rating to a “hold” rating in a research note on Monday, July 17th. Jefferies Group LLC reiterated a “hold” rating on shares of C.R. Bard in a research note on Thursday, August 3rd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of C.R. Bard in a research note on Thursday, October 26th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $292.00.
ILLEGAL ACTIVITY NOTICE: “1,339 Shares in C.R. Bard, Inc. (BCR) Purchased by Advisors Preferred LLC” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.com-unik.info/2017/11/05/1339-shares-in-c-r-bard-inc-bcr-purchased-by-advisors-preferred-llc.html.
Shares of C.R. Bard, Inc. (NYSE BCR) traded down $1.71 during trading on Friday, reaching $333.86. 620,597 shares of the company’s stock traded hands, compared to its average volume of 478,414. C.R. Bard, Inc. has a 12-month low of $203.63 and a 12-month high of $335.84. The company has a market cap of $24,335.72, a price-to-earnings ratio of 28.83, a PEG ratio of 2.55 and a beta of 0.53. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.72 and a quick ratio of 1.37.
C.R. Bard (NYSE:BCR) last announced its quarterly earnings data on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.96 by $0.06. C.R. Bard had a return on equity of 48.28% and a net margin of 14.75%. The company had revenue of $989.80 million for the quarter, compared to analysts’ expectations of $990.64 million. During the same quarter in the prior year, the firm earned $2.64 earnings per share. C.R. Bard’s revenue was up 5.1% compared to the same quarter last year. sell-side analysts forecast that C.R. Bard, Inc. will post 11.89 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be paid a $0.26 dividend. The ex-dividend date is Thursday, December 7th. This represents a $1.04 annualized dividend and a yield of 0.31%. C.R. Bard’s dividend payout ratio (DPR) is currently 13.70%.
In related news, Director David M. Barrett sold 3,344 shares of the stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $327.31, for a total value of $1,094,524.64. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider John P. Groetelaars sold 23,687 shares of the stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $318.73, for a total value of $7,549,757.51. Following the completion of the transaction, the insider now directly owns 31,445 shares in the company, valued at approximately $10,022,464.85. The disclosure for this sale can be found here. In the last three months, insiders sold 136,568 shares of company stock worth $43,932,079. 0.80% of the stock is owned by insiders.
C.R. Bard Company Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).
What are top analysts saying about C.R. Bard Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for C.R. Bard Inc. and related companies.